These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31387950)

  • 1. Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System.
    Raschi E; Antonazzo IC; La Placa M; Ardizzoni A; Poluzzi E; De Ponti F
    Oncologist; 2019 Nov; 24(11):e1228-e1231. PubMed ID: 31387950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
    Godfrey H; Jedlowski P; Thiede R
    Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea.
    Kang MG; Sohn KH; Kang DY; Park HK; Yang MS; Lee JY; Kang HR
    Yonsei Med J; 2019 Feb; 60(2):208-215. PubMed ID: 30666843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.
    Zhou J; Wang CP; Li J; Zhang HL; He CX
    Front Immunol; 2024; 15():1414136. PubMed ID: 39072330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.
    Borrelli EP; Lee EY; Descoteaux AM; Kogut SJ; Caffrey AR
    Epilepsia; 2018 Dec; 59(12):2318-2324. PubMed ID: 30395352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.
    Nguyen KD; Tran TN; Nguyen MT; Nguyen HA; Nguyen HA; Vu DH; Nguyen VD; Bagheri H
    J Clin Pharm Ther; 2019 Feb; 44(1):69-77. PubMed ID: 30129156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017.
    Kim HK; Kim DY; Bae EK; Kim DW
    J Korean Med Sci; 2020 Feb; 35(4):e17. PubMed ID: 31997613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.
    Papay J; Yuen N; Powell G; Mockenhaupt M; Bogenrieder T
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):289-96. PubMed ID: 22139991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and prognostic factors in severe cutaneous drug reactions.
    Yang MS; Kang MG; Jung JW; Song WJ; Kang HR; Cho SH; Min KU
    Int Arch Allergy Immunol; 2013; 162(4):346-54. PubMed ID: 24193402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system.
    Li C; Li Z; Sun Q; Xiang Y; Liu A
    Expert Opin Drug Saf; 2024 Jun; 23(6):777-784. PubMed ID: 37622438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of immune checkpoint inhibitor-related dermatologic adverse events.
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
    Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system.
    Ball R; Ball LK; Wise RP; Braun MM; Beeler JA; Salive ME
    Pediatr Infect Dis J; 2001 Feb; 20(2):219-23. PubMed ID: 11224848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
    Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
    Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The life-threatening eruptions of immune checkpoint inhibitor therapy.
    Coleman EL; Olamiju B; Leventhal JS
    Clin Dermatol; 2020; 38(1):94-104. PubMed ID: 32197753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.